Plasma Trimethylamine-N-oxide and impaired glucose regulation: Results from The Oral Infections, Glucose Intolerance and Insulin Resistance Study (ORIGINS)

Sumith Roy, Melana Yuzefpolskaya, Renu Nandakumar, Paolo C. Colombo, Ryan T. Demmer

1 Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, United States of America; 2 Division of Cardiology, Department of Medicine, New York Presbyterian Hospital, Columbia University, New York, NY, United States of America; 3 Irving Institute for Clinical and Translational Research, Columbia University Medical Center, New York, NY, United States of America; 4 Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN, United States of America

Abstract

Trimethylamine-N-oxide (TMAO)—a gut-microbiota metabolite—is a biomarker of cardiometabolic risk. No studies have investigated TMAO as an early biomarker of longitudinal glucose increase or prevalent impaired glucose regulation. In a longitudinal cohort study, 300 diabetes-free men and women (77%) aged 20–55 years (mean = 34±10) were enrolled at baseline and re-examined at 2-years to investigate the association between TMAO and biomarkers of diabetes risk. Plasma TMAO was measured using Ultra Performance Liquid Chromatography-Mass Spectrometry. After an overnight fast, FPG was measured longitudinally, HbA1C and insulin were measured only at baseline. Insulin resistance was defined using HOMA-IR. Multivariable generalized linear models regressed; i) FPG change (year 2 minus baseline) on baseline TMAO tertiles; and ii) HOMA-IR and HbA1c on TMAO tertiles. Multivariable relative risk regressions modeled prevalent prediabetes across TMAO tertiles.

Mean values of 2-year longitudinally FPG±SE across tertiles of TMAO were 86.6±0.9, 86.7±0.9, 86.4±0.9 (p = 0.98). Trends were null for FPG, HbA1c and insulin measured only at baseline. Insulin resistance was defined using HOMA-IR. Multivariable generalized linear models regressed; i) FPG change (year 2 minus baseline) on baseline TMAO tertiles; and ii) HOMA-IR and HbA1c on TMAO tertiles. Multivariable relative risk regressions modeled prevalent prediabetes across TMAO tertiles. Mean values of 2-year longitudinal FPG±SE across tertiles of TMAO were 86.6±0.9, 86.7±0.9, 86.4±0.9 (p = 0.98). Trends were null for FPG, HbA1c, and HOMA-IR, cross-sectionally. The prevalence ratio of prediabetes among participants in 2nd and 3rd TMAO tertiles (vs. the 1st) were 1.94 [95%CI 1.09–3.48] and 1.41 [95%CI: 0.76–2.61]. TMAO levels are associated with increased prevalence of prediabetes in a nonlinear fashion but not with insulin resistance or longitudinal FPG change.

Introduction

Type 2 diabetes is an important public health problem with over 400 million diagnosed cases globally, and in the United States the prevalence of diagnosed diabetes increased from 0.93%
in 1958 to 7.40% in 2015[1]. Similarly, impaired glucose regulation (i.e., prediabetes) is also a growing public health concern. In 2012, an estimated 86 million people in the U.S. aged 20 and older had prediabetes[1], which is a strong preclinical risk factor for future type 2 diabetes. A better understanding of disease susceptibility and environmental risk factors is needed to address the growing burden of type 2 diabetes.

The microbes inhabiting the gastrointestinal tract have been hypothesized to play an etiologic role in the development of cardiometabolic diseases. Recently, Le Chatelier et al.[2] found the gut microbiome to be associated with adverse metabolic profiles both cross-sectionally and longitudinally among diabetes-free individuals, bolstering the potential for the gut microbiota to contribute to early diabetes risk, although the mechanisms remain uncertain.

Trimethylamine-N-oxide (TMAO)–a gut microbiota derived metabolite–has been hypothesized as risk factor for cardiometabolic disease. TMAO is produced primarily by the metabolism of dietary nutrients such as choline, phosphatidylcholine and L-carnitine by intestinal bacteria to produce trimethylamine which is subsequently converted to TMAO in the liver. There is strong evidence linking circulating TMAO levels to increased risk for myocardial infarction and stroke[3, 4], even in low risk individuals (e.g., age <65 years, women, low lipid levels, low C-reactive protein (CRP) levels)[5]. In regard to diabetogenesis, animal models have shown that dietary TMAO can lead to impaired glucose tolerance, increase fasting insulin levels and adipose tissue inflammation, in mice fed a high fat diet[6]. Others have demonstrated that knockdown of flavin containing monooxygenase 3 (FMO3)–which produces TMAO–in insulin resistant mice blocks the development of hyperglycemia[7]. In humans, a few studies have also shown increased TMAO levels to be associated with type 2 diabetes. Most prior studies[8–11] were cross-sectional precluding the ability to determine whether elevated TMAO preceded type 2 diabetes development or resulted from the diabetes phenotype which is often associated with alterations in host physiology, including nephropathy, which influences TMAO levels via reduced renal clearance. Additionally, health behavior changes and new pharmacological therapies occurring in response to type 2 diabetes diagnosis could contribute to intestinal dysbiosis and increased capacity for TMAO production. To our knowledge, only one longitudinal study has explored baseline TMAO as a predictor of future diabetes development[12] and, surprisingly, they report elevated TMAO levels to be related to decreased type 2 diabetes risk. Therefore, limited data are available exploring the value of TMAO in predicting type 2 diabetes development. No existing studies have explored the relationship between TMAO and early risk biomarkers linked to future type 2 diabetes development such as insulin resistance, rising longitudinal glucose levels or prediabetes.

Presently, we have studied the relationship between plasma TMAO and early biomarkers of type 2 diabetes risk. We hypothesize that elevated plasma TMAO-levels would be associated with markers of insulin resistance and impaired glucose regulation, cross-sectionally, as well as with rising glucose levels, longitudinally. These investigations are undertaken in a diabetes-free population without a history of cardiovascular and/or kidney disease.

Materials and methods

Study population

The Oral Infections, Glucose Intolerance and Insulin Resistance Study (ORIGINS) is a longitudinal cohort study investigating the relationship between subgingival microbial community composition, systemic inflammatory phenotype and impaired glucose metabolism[13]. The current analysis includes the first 300 participants enrolled from February 2011 to May 2013. Participants were recruited via postal mailings, email blasts, posted flyers, information sessions and word-of-mouth strategies.
Inclusion criteria were as follows: Men and women aged 20–55 years without: i) Diabetes Mellitus based on self-report physician diagnosis, fasting plasma glucose (FPG) \( \geq 126 \text{ mg/dl} \) or hemoglobin A1c (HbA1c) \( \geq 6.5\% \) (48 mmol/mol); ii) self-reported history of myocardial infarction, congestive heart failure, stroke or chronic inflammatory conditions. Participants were examined at baseline and \( n = 297 \) had a TMAO assessment, and \( n = 241 \) (81\%) provided fasting blood at a two-year follow-up visit (February 2013 to December 2015\[13\]). The Institutional Review Boards of Columbia University and The University of Minnesota approved the study. All participants provided written informed consent.

Trimethylamine-N-oxide assessment

The exposure Trimethylamine-N-oxide (TMAO) was only measured once at baseline in human plasma samples using Ultra Performance Liquid Chromatography-Mass Spectrometry (UPLC-MS/MS) after protein precipitation using deuterated (D9)-TMAO as the internal standard\[14\]. UPLC-MS/MS analysis was performed on a platform comprising Eksigent ULC 100 integrated to API 4000 mass spectrometer controlled by Analyst 1.6 (ABSciex, Foster City, CA).

Laboratory measures

At baseline, FPG, serum insulin and lipids, and HbA1c were measured from blood after an overnight fast using a Cobras Integra 400 Plus (Roche Diagnostics, Indianapolis, IN, USA) as previously described\[15, 16\]. The Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) was used to define insulin resistance as previously defined\[17, 18\]. Baseline prediabetes status was defined based on either one of the below criteria being fulfilled: HbA1C of 5.7–6.4\% (39–46 mmol/mol) or FPG between 100 and 125 mg/dl\[19\]. FPG was also measured at the year 2 follow-up visit.

Risk factors

Cardiometabolic risk factors were measured by trained research assistants in space provided by a Center for Translational Science Award (CTSA). Seated systolic and diastolic blood pressures were measured in triplicate and the last two measurements were averaged. Participant body mass index (BMI) was calculated as weight in kilograms/height in meters\(^2\). Questionnaires were administered to obtain information on: age, sex, race/ethnicity (non-Hispanic Black, non-Hispanic White, Hispanic, Other), educational level (high school completion, college or vocational training, advanced degrees), cigarette smoking (current, former or never smoking and duration/intensity of smoking). Leisure-time physical activity (LTPA) was assessed and activities were converted into metabolic equivalents (METS), further categorizing them into four LTPA categories in accordance with the 2008 Physical Activity Guidelines for Americans: no LTPA reported, low (0 to \(< 500 \text{ MET min/wk})\), moderate(500 to \(< 1,000 \text{ MET min/wk})\), high(\( \geq 1000 \text{ MET min/wk})\)[20, 21]. A detailed food frequency questionnaire was administered from which The Alternative Healthy Eating Index (AHEI) score was calculated to represent diet quality based on the intake of 9 components: vegetables, fruit, nuts and soy, white or red meat, transfat, polyunsaturated or saturated fat, fiber, multivitamin use, and alcohol[22]. A higher total score of AHEI indicates a lower risk of developing chronic disease particularly chronic heart disease and diabetes[22, 23].

Statistical analysis

All statistical analyses were conducted with SAS 9.4. (SAS Institute, Cary, NC). Difference in means or prevalence of potential confounders according to TMAO levels or metabolic
variables (i.e., insulin resistance, FPG and HOMA-IR) were assessed using one-way ANOVA for continuous variables and chi-square for categorical variables. Multivariable linear models regressed natural log transformed insulin resistance (due to non-normality of the original variable), FPG or HbA1c on tertiles of TMAO, in separate regression models. TMAO was divided into tertiles to relax linearity assumptions. Sequentially adjusted regression models were formed to assess the degree of confounding by specific sets of confounders. Model 1 was unadjusted. Model 2 was adjusted for age, gender, race/ethnicity, and education. Model 3 was further adjusted for BMI, systolic blood pressure and HDL. Model 4 was further adjusted for AHEI. Tests for linear trends were performed using TMAO as a continuous variable in the aforementioned regression models. A multivariable modified Poisson regression with robust error variance was used regressed prediabetes prevalence across tertiles of TMAO; prevalence is defined as the probability of having prediabetes. Prevalence ratios and 95% confidence intervals (95%CI) are presented for the 2nd and 3rd tertiles of TMAO levels relative to the 1st tertile.

Results

Baseline characteristics

Participants had a mean age of 34±10 years, and 77% were female. Median plasma TMAO level and Interquartile range (IQR) are 2.69 μM and 1.9–4.22 μM, respectively. TMAO levels were modestly associated with increased age, Hispanic ethnicity and BMI (Table 1). Interestingly, diet quality as assessed by AHEI did not differ by TMAO level. Similarly, the AHEI subscore corresponding to meat consumption was not related to TMAO levels. Additional participant characteristics are summarized in Table 1.

Cross-sectional associations between TMAO and biomarkers of diabetes risk

TMAO levels did not explain variation in FPG, HbA1c or HOMA-IR cross-sectionally, as summarized in Table 2. Results were very consistent across varying degrees of multivariable adjustment (Table 2). After full multivariable adjustment (model 4, S1 Fig), the prevalence ratio of prediabetes among participants in the 2nd and 3rd TMAO tertiles (vs. the 1st) were 1.94 [95%CI 1.09–3.48] and 1.41 [95%CI: 0.76–2.61] and results were consistent across multivariable models (S1 Fig). When combining participants in the 2nd and 3rd tertiles, the prevalence ratio for prediabetes was 1.71, p = 0.05 in crude models although results were attenuated and lost statistical significance after multivariable adjustment (S2 Fig).

Longitudinal association between TMAO and fasting plasma glucose

There was no statistically significant association between baseline TMAO and follow-up FPG. In unadjusted models, mean follow-up FPG across tertiles of TMAO were 86.8±1, 86.9±1, 87.1 ±1 mg/dL respectively. Results were consistently null in multivariable models (S3 Fig).

Discussion

We report that TMAO levels were not associated with insulin resistance, HbA1c or fasting plasma glucose cross-sectionally, or with longitudinal change in fasting plasma glucose. TMAO levels were associated with a modest increase in the prevalence of prediabetes in a non-linear fashion such that participants with intermediate TMAO levels had a statistically significant 94% increase in prediabetes prevalence. These results were generally consistent regardless of level of risk factor adjustment although statistical significance was lost for participants in the highest TMAO tertile.
To our knowledge, the current study is the first to investigate the association between plasma TMAO and early biomarkers of diabetes risk among participants free of diabetes and clinical cardiovascular disease. Our null findings might appear at odds with several studies reporting that elevated TMAO levels predict increased risk for chronic kidney disease, myocardial infarction, stroke and heart failure[5, 24]. However, it is important to note that among studies with positive TMAO findings, the enrolled participants were generally older and had

Table 1. Participant characteristics overall and by TMAO Tertiles: (ORIGINS) 2011–2015.

|                           | All (N = 297) | Tertile 1 (n = 99) | Tertile 2 (n = 99) | Tertile 3 (n = 99) | P Value |
|---------------------------|--------------|-------------------|-------------------|-------------------|---------|
| TMAO (median, range)      | 2.69(1.90–4.22) | 1.73 (1.41–1.90)  | 2.69(2.33–2.98)   | 5.52(4.22–7.66)   | N/A     |
| Age,years                 | 34.06±9.86  | 32.28±0.92        | 33.87±0.98        | 36.01±1.03        | 0.02    |
| Female                    | 77.10%      | 78.79%            | 77.78%            | 74.75%            | 0.78    |
| Hispanic                  | 46.80%      | 49.50%            | 34.34%            | 56.57%            | 0.56    |
| Non-Hispanic White        | 22.90%      | 23.23%            | 26.26%            | 19.19%            | 0.45    |
| Non-Hispanic Black        | 16.84%      | 11.11%            | 20.20%            | 19.19%            | 0.45    |
| Other                     | 13.46%      | 16.16%            | 19.20%            | 5.05%             | 0.09    |
| Race                      |              |                   |                   |                   | 0.007   |
| Education                 |              |                   |                   |                   | 0.5     |
| < college                 | 31.99%      | 26.26%            | 32.32%            | 37.38%            |         |
| 4 years of college        | 45.45%      | 51.52%            | 44.45%            | 40.40%            |         |
| > college                 | 22.56%      | 22.22%            | 23.23%            | 22.22%            |         |
| Activity level            |              |                   |                   |                   | 0.59    |
| None                      | 30.58%      | 31.26%            | 32.65%            | 27.84%            |         |
| Low                       | 12.03%      | 8.33%             | 13.27%            | 14.43%            |         |
| Moderate                  | 16.15%      | 14.58%            | 19.39%            | 14.43%            |         |
| High                      | 41.24%      | 45.83%            | 34.69%            | 43.30%            |         |
| AHEI Score                | 49.05±11.88 | 48.3±1.2          | 50.2±1.3          | 48.7±1.3          | 0.53    |
| AHEI meat score           | 6.20±3.50   | 6.6±0.1           | 6.0±0.1           | 6.0±0.1           | 0.41    |
| BMI (kg/m²)               | 27.07±6.13  | 26.83±0.61        | 26.08±0.52        | 28.29±0.68        | 0.03    |
| Body Mass Index category  |              |                   |                   |                   | 0.04    |
| Normal                    | 44.44%      | 50.51%            | 50.51%            | 32.32%            |         |
| Overweight                | 32.33%      | 28.28%            | 31.31%            | 37.37%            |         |
| Obese                     | 23.23%      | 21.21%            | 18.18%            | 30.30%            |         |
| Systolic blood pressure, mm Hg | 117.75±12.45 | 117 ±1.2          | 117±1.33          | 119±1.20          | 0.52    |
| Diastolic blood pressure, mmHg | 75.25±9.71  | 75 ±0.91          | 75±1.05           | 75±0.96           | 0.98    |
| Hypertension              | 97 (32.66%) | 29 (29.29%)       | 33(33.33%)        | 35 (35.35%)       | 0.65    |
| Prediabetes               | 17.85%      | 12.12%            | 21.21%            | 20.20%            | 0.19    |
| FPG (mg/dl)               | 85.22±7.64  | 85.23±0.82        | 84.15±0.69        | 86.28±0.77        | 0.15    |
| HbA1c (%)/ mmol/mol       | 5.36±0.34   | 5.32±0.03 (35±0.3) | 5.36±0.03 (35±0.3) | 5.39±0.03 (35±0.3) | 0.38    |
| Total cholesterol (mg/dl) | 172.61±30.74 | 173.56±3.15       | 174.22±3.04       | 170.06±3.10       | 0.59    |
| LDL-cholesterol (mg/dl)** | 97.98±27.86 | 99.98±2.96        | 98.33±2.79        | 95.63±2.66        | 0.54    |
| HDL (mg/dl)               | 59.05±16.06 | 58.26±1.60        | 59.84±1.58        | 59.04±1.66        | 0.79    |
| Chol to HDL ratio         | 3.12±0.05   | 3.18±0.11         | 3.10±0.09         | 3.08±0.09         | 0.75    |
| Triglyceride (mg/dl)      | 77.80±45.50 | 77.12±3.80        | 79.61±5.24        | 76.66±4.59        | 0.89    |
| Insulin (median, 25th 75th percentile) | 8.8(5.9,12.0) | 8.5 (5.8,12.5) | 8.0 (5.6,11.3) | 9.7 (6.7,12.3) | 0.14 |
| HOMA-IR (median, 25th 75th percentile) | 0.57(0.19,0.97) | 0.54(0.15,1.03) | 0.47(0.13,0.82) | 0.70(0.31,1.04) | 0.08 |

* Standard deviation
** n = 4 participants missing LDL-cholesterol

https://doi.org/10.1371/journal.pone.0227482.t001
evidence of substantial pre-existing cardiovascular disease. For example, in the elegant publications by Tang and colleagues, study participants were recruited from elective diagnostic cardiac catheterization[8] which is an indication for suspected atherosclerotic coronary artery disease and an adverse cardiovascular risk profile. Accordingly, those participants had a mean FPG in the prediabetes range (102 mg/dl), 32% had diagnosed diabetes (~double the national rate) and 72% were hypertensive[5]. Participant characteristics were consistent in a second report among a similar patient population enrolled from recipients of elective cardiac catheterizations in which TMAO was predictive of all-cause mortality among patients with chronic kidney disease[24].

In contrast, our results from ORIGINS are consistent with recent null findings among 817 participants in the Coronary Artery Risk Development in Young Adults (CARDIA study[25] which found no association between TMAO and coronary artery calcification incidence or progression. Additionally, CARDIA also reported no association between TMAO level and cross-sectional insulin resistance. As suggested by the CARDIA investigators, the younger age (~40 years) and lower cardiovascular risk (~4% prevalent diabetes and 10% using hypertensive medications) of their cohort might explain their null finding[25]. The mean age of ORIGINS participants is similarly young (34 years) while the mean age in prior positive studies was 66 years[24] and 63 years[5]. Our observation that TMAO was modestly related to increased pre-diabetes prevalence supports the notion that TMAO levels might only be a predictive biomarker in populations with early or established cardiovascular risk.

Renal function might also provide some level of explanation for discordant findings in our current data as compared to other cohorts. The fact that higher renal function increases evidence of substantial pre-existing cardiovascular disease. For example, in the elegant publications by Tang and colleagues, study participants were recruited from elective diagnostic cardiac catheterization[8] which is an indication for suspected atherosclerotic coronary artery disease and an adverse cardiovascular risk profile. Accordingly, those participants had a mean FPG in the prediabetes range (102 mg/dl), 32% had diagnosed diabetes (~double the national rate) and 72% were hypertensive[5]. Participant characteristics were consistent in a second report among a similar patient population enrolled from recipients of elective cardiac catheterizations in which TMAO was predictive of all-cause mortality among patients with chronic kidney disease[24].

In contrast, our results from ORIGINS are consistent with recent null findings among 817 participants in the Coronary Artery Risk Development in Young Adults (CARDIA study[25] which found no association between TMAO and coronary artery calcification incidence or progression. Additionally, CARDIA also reported no association between TMAO level and cross-sectional insulin resistance. As suggested by the CARDIA investigators, the younger age (~40 years) and lower cardiovascular risk (~4% prevalent diabetes and 10% using hypertensive medications) of their cohort might explain their null finding[25]. The mean age of ORIGINS participants is similarly young (34 years) while the mean age in prior positive studies was 66 years[24] and 63 years[5]. Our observation that TMAO was modestly related to increased pre-diabetes prevalence supports the notion that TMAO levels might only be a predictive biomarker in populations with early or established cardiovascular risk.

Renal function might also provide some level of explanation for discordant findings in our current data as compared to other cohorts. The fact that higher renal function increases evidence of substantial pre-existing cardiovascular disease. For example, in the elegant publications by Tang and colleagues, study participants were recruited from elective diagnostic cardiac catheterization[8] which is an indication for suspected atherosclerotic coronary artery disease and an adverse cardiovascular risk profile. Accordingly, those participants had a mean FPG in the prediabetes range (102 mg/dl), 32% had diagnosed diabetes (~double the national rate) and 72% were hypertensive[5]. Participant characteristics were consistent in a second report among a similar patient population enrolled from recipients of elective cardiac catheterizations in which TMAO was predictive of all-cause mortality among patients with chronic kidney disease[24].

In contrast, our results from ORIGINS are consistent with recent null findings among 817 participants in the Coronary Artery Risk Development in Young Adults (CARDIA study[25] which found no association between TMAO and coronary artery calcification incidence or progression. Additionally, CARDIA also reported no association between TMAO level and cross-sectional insulin resistance. As suggested by the CARDIA investigators, the younger age (~40 years) and lower cardiovascular risk (~4% prevalent diabetes and 10% using hypertensive medications) of their cohort might explain their null finding[25]. The mean age of ORIGINS participants is similarly young (34 years) while the mean age in prior positive studies was 66 years[24] and 63 years[5]. Our observation that TMAO was modestly related to increased pre-diabetes prevalence supports the notion that TMAO levels might only be a predictive biomarker in populations with early or established cardiovascular risk.

Renal function might also provide some level of explanation for discordant findings in our current data as compared to other cohorts. The fact that higher renal function increases evidence of substantial pre-existing cardiovascular disease. For example, in the elegant publications by Tang and colleagues, study participants were recruited from elective diagnostic cardiac catheterization[8] which is an indication for suspected atherosclerotic coronary artery disease and an adverse cardiovascular risk profile. Accordingly, those participants had a mean FPG in the prediabetes range (102 mg/dl), 32% had diagnosed diabetes (~double the national rate) and 72% were hypertensive[5]. Participant characteristics were consistent in a second report among a similar patient population enrolled from recipients of elective cardiac catheterizations in which TMAO was predictive of all-cause mortality among patients with chronic kidney disease[24].

In contrast, our results from ORIGINS are consistent with recent null findings among 817 participants in the Coronary Artery Risk Development in Young Adults (CARDIA study[25] which found no association between TMAO and coronary artery calcification incidence or progression. Additionally, CARDIA also reported no association between TMAO level and cross-sectional insulin resistance. As suggested by the CARDIA investigators, the younger age (~40 years) and lower cardiovascular risk (~4% prevalent diabetes and 10% using hypertensive medications) of their cohort might explain their null finding[25]. The mean age of ORIGINS participants is similarly young (34 years) while the mean age in prior positive studies was 66 years[24] and 63 years[5]. Our observation that TMAO was modestly related to increased pre-diabetes prevalence supports the notion that TMAO levels might only be a predictive biomarker in populations with early or established cardiovascular risk.
TMAO clearance raises the strong potential for confounding. Specifically, it is possible that reduced renal function causes both elevated TMAO levels and clinical cardiovascular disease (CVD) events. Our observation of increased TMAO among older participants provides indirect support for this notion. As such, our adjustment for age in multivariable models helps to mitigate confounding by renal function although future studies with assessment of renal function will be important.

It is also possible that the adverse impact of TMAO on cardiometabolic risk, only begins above a threshold of circulating TMAO that is achieved in the context of reduced renal function enabling excessive TMAO accumulation. Interestingly, Tang and colleagues found that among patients without chronic kidney disease (CKD), the predictive value of TMAO for all-cause mortality was substantially diminished and only statistically significant in the 4th TMAO quartile[24]. Moreover, the observed range of TMAO values in the non-statistically significant 1st–3rd quartiles of TMAO were similar to the ranges observed in both CARDIA and ORIGINS. Median (IQR) plasma TMAO levels in ORIGINS are 2.7 μM (1.9–4.22 μM) and in CARDIA median (IQR) values were 2.6 (1.8–4.2).[25]

Some important limitations should be noted. The ORIGINS cohort is not a nationally representative sample, limiting the generalizability of our findings. Nevertheless, the consistency in TMAO distributions between ORIGINS and CARDIA, a much larger multi-center, population-based study, suggests that results in ORIGINS are robust. Second, our sample size was small and had limited power to rule out associations of very modest magnitude. Nevertheless, the magnitude of associations observed presently are unlikely to be clinically meaningful even if larger studies identified statistically significant findings of similar magnitude. Our measure of diet quality was based on a single food frequency questionnaire which potentially mischaracterized TMAO dietary precursors proximal to the assessment of TMAO. Dietary information in the study was calculated using AHEI[22], which is based on foods and nutrients predictive of chronic disease risk generally and not TMAO specifically. Regardless, since TMAO is hypothesized as an intermediate mechanism linking diet to cardiometabolic outcomes, the dietary assessment poses minimal threat to the validity of our TMAO findings. In future studies, the precision of hypothesis tests would be enhanced by measuring gut microbiome and dietary TMAO precursors carefully, and analyzing the potential for interactions between the gut microbiome and diet on TMAO levels and subsequent cardiometabolic disease.

A strength of our study was the ability to examine the prospective association of baseline plasma TMAO levels and longitudinal changes in fasting plasma glucose among a healthy study sample which precludes potential reverse causation by the diabetes phenotype and reduces potential confounding by reduced renal function.

In a cohort of participants free of diabetes and clinical cardiovascular disease, we observed no association between TMAO levels and continuous biomarkers of early diabetes risk cross-sectionally or longitudinally. In contrast, intermediate TMAO levels were modestly associated with increased risk of prevalent prediabetes after multivariable adjustment. Future longitudinal studies are necessary to determine if TMAO increases risk for incident prediabetes and/or diabetes, despite no evident relationships with insulin resistance. Until such studies are performed, the role of TMAO as a biomarker of diabetes risk remains uncertain.

Supporting information

S1 Fig. Association between Tertiles of TMAO and Prediabetes Prevalence. Model 1 = unadjusted; Model 2 = age, gender, race/ethnicity, education; Model 3 = M2+ BMI, systolic blood pressure, HDL; Model 4 = M3+ alternative healthy eating index. *p<0.05. (TIF)
S2 Fig. Association between TMAO (Tertiles 2 and 3 vs. 1) and Prediabetes Prevalence. Model 1 = unadjusted; Model 2 = age, gender, race/ethnicity, education; Model 3 = M2+ BMI, systolic blood pressure, HDL; Model 4 = M3+ alternative healthy eating index. (TIF)

S3 Fig. Association between Baseline TMAO Tertiles and Longitudinal Fasting Plasma Glucose. Model 1 = unadjusted; Model 2 = age, gender, race/ethnicity, education; Model 3 = M2+BMI, systolic blood pressure, HDL+ alternative healthy eating index; Model 4 = M3+ baseline glucose. Y axis is centered on the mean value observed in the total population (mean = 85 mg/dL) and the range is set to twice the standard deviation of fasting glucose. (TIF)

Acknowledgments
We thank the following individuals for their invaluable contributions to this research: the 1199 SEIU, HS-3/SSA Area leadership including Ms. Consuelo Mclaughin, Mr. Bennett Batista, Mr. Victor Rivera; Ms. Romanita Celenti for her efforts in performing phlebotomy and processing and analyzing plaque samples; Ms. Aleksandra Zuk and Garazi Zulaika for their leadership and excellent program coordination; Drs. Nidhi Arora, Ashwata Pokherel, Publio Silfa & Thomas Spinell for their skilled examinations and essential participant engagement. We are also profoundly grateful to the ORIGINS participants, for their participation in this research.

Author Contributions
Conceptualization: Sumith Roy, Ryan T. Demmer.
Funding acquisition: Ryan T. Demmer.
Writing – original draft: Sumith Roy, Ryan T. Demmer.
Writing – review & editing: Sumith Roy, Melana Yuzefpolskaya, Renu Nandakumar, Paolo C. Colombo, Ryan T. Demmer.

References
1. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States. Atlanta, GA: Centers for Disease Control and Prevention, 2014.
2. Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013; 500(7464):541–6. https://doi.org/10.1038/nature12506 PMID: 23985870.
3. Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nature medicine. 2013; 19(5):576–85. Epub 2013/04/09. https://doi.org/10.1038/nm.3145 PMID: 23563705; PubMed Central PMCID: PMC3650111.
4. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011; 472(7341):57–63. Epub 2011/04/09. https://doi.org/10.1038/nature09922 PMID: 21475195; PubMed Central PMCID: PMC3086762.
5. Tang WH, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. The New England journal of medicine. 2013; 368(17):1575–84. Epub 2013/04/26. https://doi.org/10.1056/NEJMoa1109400 PMID: 23614584; PubMed Central PMCID: PMC3701945.
6. Gao X, Liu X, Xu J, Xue C, Xue Y, Wang Y. Dietary trimethylamine N-oxide exacerbates impaired glucose tolerance in mice fed a high fat diet. Journal of bioscience and bioengineering. 2014; 118(4):476–81. Epub 2014/04/12. https://doi.org/10.1016/j.jbiosc.2014.03.001 PMID: 24721123.
7. Miao J, Ling AV, Manthena PV, Gearing ME, Graham MJ, Crooke RM, et al. Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis. Nature communications. 2015;
8. Tang WH, Wang Z, Fan Y, Levison B, Hazen JE, Donahue LM, et al. Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis. J Am Coll Cardiol. 2014; 64(18):1908–14. Epub 2014/12/03. https://doi.org/10.1016/j.jacc.2014.02.617 PMID: 25444145; PubMed Central PMCID: PMC4254529.

9. Shan Z, Sun T, Huang H, Chen S, Chen L, Luo C, et al. Association between microbiota-dependent metabolite trimethylamine-N-oxide and type 2 diabetes. The American journal of clinical nutrition. 2017; 106(3):888–94. Epub 2017/07/21. https://doi.org/10.1093/ajcn/nmx056 PMID: 27824646.

10. Dambrova M, Latkovskis G, Kuka J, Strele I, Konrade I, Grinberg S, et al. Diabetes is Associated with Higher Trimethylamine N-Oxide Plasma Levels. Exp Clin Endocrinol Diabetes. 2016; 124(4):251–6. Epub 2016/04/29. https://doi.org/10.1055/s-0035-15699330 PMID: 27123785.

11. Lever M, George PM, Slow S, Bellamy D, Young JM, Ho M, et al. Betaine and Trimethylamine-N-Oxide as Predictors of Cardiovascular Outcomes Show Different Patterns in Diabetes Mellitus: An Observational Study. PLoS One. 2014; 9(12):e114969. Epub 2014/12/11. https://doi.org/10.1371/journal.pone.0114969 PMID: 25493436; PubMed Central PMCID: PMC4262445.

12. Papandreou C, Bullo M, Zheng Y, Ruiz-Canela M, Yu E, Guasch-Ferre M, et al. Plasma trimethylamine-N-oxide and related metabolites are associated with type 2 diabetes risk in the Prevencion con Dieta Mediterranea (PREDIMED) trial. The American journal of clinical nutrition. 2018; 108(1):163–73. https://doi.org/10.1093/ajcn/nqy058 PMID: 29982310.

13. Demmer RT, Jacobs DR Jr., Singh R, Zuk A, Rosenbaum M, Papapanou PN, et al. Periodontal Bacteria and Prediabetes Prevalence in ORIGINS: The Oral Infections, Glucose Intolerance, and Insulin Resistance Study. Journal of dental research. 2015; 94(9 Suppl):201s–11s. Epub 2015/06/18. https://doi.org/10.1177/0022034515590369 PMID: 26063877; PubMed Central PMCID: PMC4547206.

14. Wang Z, Levison BS, Hazen JE, Donahue L, Li XM, Hazen SL. Measurement of trimethylamine-N-oxide by stable isotope dilution liquid chromatography tandem mass spectrometry. Analytical biochemistry. 2014; 455:35–40. Epub 2014/04/08. https://doi.org/10.1016/j.ab.2014.03.016 PMID: 24704102; PubMed Central PMCID: PMC4167037.

15. Demmer RT, Breskin A, Rosenbaum M, Zuk A, LeDuc C, Leibel R, et al. The Subgingival Microbiome, Systemic Inflammation and Insulin Resistance: The Oral Infections, Glucose Intolerance and Insulin Resistance Study (ORIGINS). J Clin Periodontol. 2016. https://doi.org/10.1111/jcpe.12664 PMID: 27978598.

16. Demmer RT, Jacobs Jr. DR., Singh R, Zuk A, Rosenbaum M, Papapanou PN, et al. Periodontal Bacteria and Prediabetes Prevalence in ORIGINS: The Oral Infections, Glucose Intolerance, and Insulin Resistance Study. J Dent Res. 2015. https://doi.org/10.1177/0022034515590369 PMID: 26062837.

17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28(7):412–9. Epub 1985/07/01. https://doi.org/10.1007/bf00280883 PMID: 3899825.

18. Demmer RT, Squillaro A, Papapanou PN, Rosenbaum M, Friedewald WT, Jacobs Jr. DR., et al. Periodontal Infection, Systemic Inflammation, and Insulin Resistance: Results from the Continuous National Health and Nutrition Examination Survey (NHANES) 1999–2004. Diabetes Care. 2012; 35(11):2235–42. Epub 2012/07/28. https://doi.org/10.2337/dc12-0072 PMID: 22837730.

19. Diagnosis and classification of diabetes mellitus. Diabetes care. 2014; 37 Suppl 1:S81–90. Epub 2013/12/21. https://doi.org/10.2337/dc14-S081 PMID: 24357215.

20. Ainsworth BE, Haskell WL, Leon AS, Jacobs DR Jr., Montoye HJ, Sallis JF, et al. Compendium of physical activities: classification of energy costs of human physical activities. Medicine and science in sports and exercise. 1993; 25(1):71–80. Epub 1993/01/01. https://doi.org/10.1249/00005768-19930100-00011 PMID: 8292105.

21. Thai A, Papapanou PN, Jacobs DR Jr., Desvarieux M, Demmer RT. Periodontal infection and cardiorenal fitness in younger adults: results from continuous national health and nutrition examination survey 1999–2004. PLoS One. 2014; 9(3):e92441. https://doi.org/10.1371/journal.pone.0092441 PMID: 24663097; PubMed Central PMCID: PMC3693905.

22. Chiue SE, Fung TT, Rimm EB, Hu FB, McCullough ML, Wang M, et al. Alternative dietary indices both strongly predict risk of chronic disease. J Nutr. 2012; 142(6):1009–18. https://doi.org/10.3945/jn.111.157222 PMID: 22513989; PubMed Central PMCID: PMC3738221.

23. McCullough ML, Feskanch D, Stampfer MJ, Giovannucci EL, Rimm EB, Hu FB, et al. Diet quality and major chronic disease risk in men and women: moving toward improved dietary guidance. The American journal of clinical nutrition. 2002; 76(6):1261–71. Epub 2002/11/27. https://doi.org/10.1093/ajcn/76.6.1261 PMID: 12450892.
24. Tang WH, Wang Z, Kennedy DJ, Wu Y, Buffa JA, Agatisa-Boyle B, et al. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res. 2015; 116(3):448–55. Epub 2015/01/20. https://doi.org/10.1161/CIRCRESAHA.116.305360 PMID: 25599331; PubMed Central PMCID: PMC4312512.

25. Meyer KA, Benton TZ, Bennett BJ, Jacobs DR Jr., Lloyd-Jones DM, Gross MD, et al. Microbiota-Dependent Metabolite Trimethylamine N-Oxide and Coronary Artery Calcium in the Coronary Artery Risk Development in Young Adults Study (CARDIA). Journal of the American Heart Association. 2016; 5 (10). Epub 2016/10/30. https://doi.org/10.1161/jaha.116.003970 PMID: 27792658; PubMed Central PMCID: PMC5121500.